Skip to main content

Market Overview

Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies

  • Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis.
  • The analyses compare changes in functional composite scores over the study treatment period to the baseline. 
  • The overall study population showed notable increasing mean improvements in overall functional scores and key functional sub-scales compared to the comparator group at each visit.
  • Unblinded topline data are expected in the first half of 2022.
  • In a second presentation, interim results from the REPAIR-MS Phase 2 study to evaluate the effects of orally administered CNM-Au8 on the metabolic profile of MS patient brains demonstrate significant CNS target engagement of CNM-Au8. Topline data expected in the second half of 2021.
  • CNM-Au8, a bioenergetic nanocatalyst, is a stable, aqueous suspension of catalytically active gold (Au) nanocrystals.
  • Clean surfaced nanocrystalline CNM-Au8 drives critical cellular bioenergetic reactions in the brain to increase cellular energy, accelerate neuro repair, and improve neuroprotection.
  • Price Action: CLNN shares are down 5.8% at $13.69 in market trading hours on the last check Thursday.

Related Articles (CLNN)

View Comments and Join the Discussion!

Posted-In: multiple sclerosis Phase 2 Clinical TrialBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at